Respiratory disease

Respiratory Disease Vaccine Market Size, Share & Trends Analysis Report 2023 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 12, 2023
Health, Pharmaceutical, Viral, Pfizer, Research, RSV, Market, Combination, Pneumonia, Incidence, Ageing, Urinary tract infection, Investment, Risk, Traction, Vaccination, Respiratory disease, FDA, Vaccine, USD, Influenza, COVID-19, Infection, Growth, SARS-CoV-2, Pharmaceutical industry

The "Respiratory Disease Vaccine Market Size, Share & Trends Analysis Report By Type (Viral, Bacterial, Combination), By Age Group, By Infection (COVID-19, Influenza), By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Respiratory Disease Vaccine Market Size, Share & Trends Analysis Report By Type (Viral, Bacterial, Combination), By Age Group, By Infection (COVID-19, Influenza), By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global respiratory disease vaccine market size is expected to reach USD 70.30 billion by 2030, expanding at a CAGR of 1.21% from 2023 to 2030
    The growth of the respiratory disease vaccine market is attributable to increasing awareness associated with the importance of vaccination, the rising incidence of respiratory infections, and advancements in vaccine technology.
  • Moreover, the COVID-19 pandemic has brought significant traction to the importance of respiratory vaccines which has further accelerated the market.
  • In recent years, the respiratory vaccine market has witnessed substantial growth attributed to advancements in vaccine technology, specifically in the development of vaccines targeting SARS-CoV-2.

Celiac Disease Foundation Teams Up with Mark Cuban Cost Plus Drug Company

Retrieved on: 
Wednesday, December 6, 2023
Retail, Health, Other Retail, Fitness & Nutrition, General Health, Pharmaceutical, Policy, Cost Plus Drugs, Food, Pharmacist, Risk, Mortality, Cardiovascular disease, Patient, Multimedia, Respiratory disease, Private sector, World Market (store), Social media, Cancer, Diagnosis, Coeliac disease, Lymphoma, Dentistry

The Celiac Disease Foundation , a global leader in celiac disease patient advocacy, today announces its new relationship with Mark Cuban Cost Plus Drug Company ( Cost Plus Drugs ) to provide resources for celiac disease patients and all consumers concerned about potential gluten in the company’s medications.

Key Points: 
  • The Celiac Disease Foundation , a global leader in celiac disease patient advocacy, today announces its new relationship with Mark Cuban Cost Plus Drug Company ( Cost Plus Drugs ) to provide resources for celiac disease patients and all consumers concerned about potential gluten in the company’s medications.
  • We are pleased and proud to join forces with Mark Cuban Cost Plus Drug Company to provide peace of mind to our celiac disease community.”
    Cost Plus Drugs’ pharmacy fulfillment partners can address inquiries regarding gluten content in medications, ensuring that those with celiac disease can confidently navigate their needs with the guidance of knowledgeable pharmacists.
  • “We are thrilled to be working with the Celiac Disease Foundation,” said Dr. Alex Oshmyansky, CEO of Mark Cuban Cost Plus Drug Company.
  • Living with celiac disease is a daily struggle, and it also increases the mortality risks for cancer, cardiovascular disease, and respiratory disease.

Respiratory Disease Testing Market Size & Trends Analysis 2023 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 28, 2023
Health, General Health, COPD, Prevalence, Medtronic, BD (company), Application, Respiratory disease, Patient, Occupational lung disease, Airway management, USD, Chronic obstructive pulmonary disease, CareFusion, CT scan, Diagnosis, Growth, Respironics, Asthma, NIV, Medical device, Pharmaceutical industry, Medical imaging

The "Respiratory Disease Testing Market Size, Share & Trends Analysis Report By Product (Imaging Tests, Respirometers, Blood Gas Tests), By End-use, By Application, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Respiratory Disease Testing Market Size, Share & Trends Analysis Report By Product (Imaging Tests, Respirometers, Blood Gas Tests), By End-use, By Application, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global respiratory disease testing market size is expected to reach USD 7.75 billion by 2030, registering a CAGR of 2.8% from 2023 to 2030
    The market is driven by the rising prevalence of respiratory diseases.
  • Along with technological advancements, use of digital radiography (X-ray) and advanced portable spirometers is gaining momentum in the respiratory disease testing/diagnostics market.
  • These players are strong brands in the market as they have elaborate product portfolios in respiratory disease diagnostics market

Inhalon Biopharma Secures U.S. Army Medical Research and Development Command Award to Support Development of Inhaled Therapeutics for Treatment of COVID-19

Retrieved on: 
Wednesday, November 15, 2023
Biotechnology, Health, Homeland Security, Military, Public Policy, Government, Pharmaceutical, Defense, Research, Medical Devices, Infectious Diseases, Contracts, Science, COVID-19, Clinical Trials, Disease, Department of Defence, Policy, Respiratory disease, Patient, Infection, Pharmacokinetics, ARI, Army, Virus, Trial of the century, Antibody, SARS-CoV-2, SARS, News, Unitary state, Vaccine, Pharmaceutical industry

The company will use the funds to develop a new self-administered, broad-spectrum antiviral for prophylaxis or treatment of SARS viruses, designed to be potent against all current and future variants of SARS-CoV-2, the virus causing COVID-19.

Key Points: 
  • The company will use the funds to develop a new self-administered, broad-spectrum antiviral for prophylaxis or treatment of SARS viruses, designed to be potent against all current and future variants of SARS-CoV-2, the virus causing COVID-19.
  • “The rapid evolution of SARS-CoV-2 has made it difficult for the medical community to effectively protect the population from COVID-19 infection and to develop treatments that remain effective against a changing virus,” said John Whelan, president and chief executive officer, Inhalon Biopharma.
  • This award follows an earlier award from USAMRDC showing proof-of-concept for the Inhalon Biopharma inhaled antibody treatment approach.
  • In a clinical study funded under that award, Inhalon Biopharma demonstrated that an anti-SARS-CoV-2 antibody could be safely and effectively delivered to healthy volunteers.

CDC's Fall and Winter Virus Season Communications Effort Appeals to What We Hold Dearest

Retrieved on: 
Monday, December 11, 2023
Perception, Ventilation, Health equity, RSV, Incidence, Mortality, Vaccination, Respiratory disease, Death, Vaccine, Health, COVID-19, Friends, Virus, MPH, CDC, Hospital, MD

ATLANTA, Dec. 11, 2023 /PRNewswire/ -- The Centers for Disease Control and Prevention (CDC) has a new communications effort to address the anticipated increase of flu, COVID-19, and RSV cases this fall and winter virus season. Similar respiratory disease activity in recent years has resulted in high hospitalization and mortality rates in the United States, highlighting the critical need for clear communications around virus prevention to help Americans protect their health.

Key Points: 
  • ATLANTA, Dec. 11, 2023 /PRNewswire/ -- The Centers for Disease Control and Prevention (CDC) has a new communications effort to address the anticipated increase of flu, COVID-19, and RSV cases this fall and winter virus season.
  • "As we head into this respiratory virus season, we are starting from a place of strength.
  • Creative elements encourage vaccination and other preventive steps during fall and winter gathering season, while also increasing awareness and perception of severity of respiratory diseases.
  • Today's fall and winter virus season challenges require collaboration and coordination with a wide variety of partners to advance essential information that helps protect communities against the worst of these respiratory viruses.

Alveolus Bio Enters Into Strategic Collaboration with BiomEdit

Retrieved on: 
Friday, December 8, 2023
Pet, Research, Disease, Coronavirus, Respiratory disease, Science, Animal, Eli Lilly, Therapy, Alveolus, Partnership, Human, Elanco, Synthetic biology

and BIRMINGHAM, Ala., Dec. 8, 2023 /PRNewswire/ -- Alveolus Bio today announced a strategic scientific collaboration with BiomEdit, an emerging animal health biotechnology company leveraging microbiome science and synthetic biology to develop novel products to prevent and treat disease in animals.

Key Points: 
  • and BIRMINGHAM, Ala., Dec. 8, 2023 /PRNewswire/ -- Alveolus Bio today announced a strategic scientific collaboration with BiomEdit, an emerging animal health biotechnology company leveraging microbiome science and synthetic biology to develop novel products to prevent and treat disease in animals.
  • BiomEdit, founded in 2022, originated through a carveout from Elanco Animal Health, formerly a division of Eli Lilly, in a strategic partnership with Ginkgo Bioworks.
  • Alveolus Bio will be studying BiomEdit's proprietary consortium of commensal strains, which secrete metabolites with documented anti-inflammatory and immune-modulating properties.
  • "This collaboration with BiomEdit shows great potential for fortifying Alveolus' asset pipeline and advancing BiomEdit's bioproduct delivery capabilities," remarked Gaurav Mehta, Chief Executive Officer of Alveolus Bio.

Olympic and World Champion Swimmer Maggie Mac Neil: "I understand the real fear of not being able to take a deep breath"

Retrieved on: 
Wednesday, December 6, 2023
Smoke, Paris Olympics, COPD, Next Generation, Breast, Way, Research, Depression, Respiratory disease, Education, RSV, LHF, Conditional sentence, Pneumonia, Ambassador, Shock, RSVP, Gold, Asthma, Gift, Long-term care, Prostate cancer, Lung cancer, Death, Survivor, Maggie Mac Neil, Hospital, Life, Fossil fuel, Medical device, Pharmaceutical industry, Poultry farming, Tobacco, Smoking

non-smoker have in common with elite Canadian athlete Maggie Mac Neil, who will defend her gold medal and world record in the 100m butterfly at the Paris Olympics next summer?

Key Points: 
  • non-smoker have in common with elite Canadian athlete Maggie Mac Neil, who will defend her gold medal and world record in the 100m butterfly at the Paris Olympics next summer?
  • If you are worried about your breathing; if you are struggling to breathe, seek help from a healthcare professional.
  • There is a treatment out there for you, and the Lung Health Foundation is there to guide and support you."
  • The flu and pneumonia consistently remain in the top 10 leading causes of death in Canada.

Imre Underscores Commitment to Client Experience with the Appointment of Scott Tucker as its First Chief Client Officer

Retrieved on: 
Thursday, November 30, 2023
Traffic, CNS, Men's Health, Woman, Courage, Depression, Erg, HIV/AIDS, Aladar Imre, Imre, Cardiovascular disease, Respiratory disease, Publicis, Omnicom Group, Mentorship, Culture, Havas, IPG, Growth, Diversity, Employee resource group, Management

NEW YORK, Nov. 30, 2023 /PRNewswire/ -- Today imre announces the appointment of Scott Tucker as its first Chief Client Officer underscoring its commitment to growth through excellence in delivering the best experience and creative product for its clients. Scott's appointment strengthens the agency's Executive Leadership Team.

Key Points: 
  • NEW YORK, Nov. 30, 2023 /PRNewswire/ -- Today imre announces the appointment of Scott Tucker as its first Chief Client Officer underscoring its commitment to growth through excellence in delivering the best experience and creative product for its clients.
  • Scott brings 30 years of agency experience to imre, beginning at what became known as Grey Healthcare Group in their Traffic department followed before entering Account Services.
  • Since that time, Scott has grown his career in Account Management and Client Services through increasing leadership roles at agency networks including IPG, Omnicom, Publicis and Havas Health.
  • At imre, Scott will work closely with all levels of the agency's client experience team and will be an active participant in account planning.

Chiesi Group signed a License Agreement with Haisco Pharmaceutical to develop, manufacture, and commercialise a novel, reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis

Retrieved on: 
Monday, November 20, 2023
Bronchiectasis, Respiratory disease, Patient, End-user license agreement, Partnership, DPP1, Pharmaceutical industry, Chiesi Farmaceutici

Chiesi Group and Haisco Pharmaceutical will collaborate closely to develop HSK31858, a novel reversible dipeptidyl peptidase 1 (DPP1) inhibitor for respiratory diseases.

Key Points: 
  • Chiesi Group and Haisco Pharmaceutical will collaborate closely to develop HSK31858, a novel reversible dipeptidyl peptidase 1 (DPP1) inhibitor for respiratory diseases.
  • This agreement expands Chiesi's comprehensive R&D program in bronchiectasis, a respiratory disease with high unmet medical needs, for which no approved treatment is available to date.
  • Haisco Pharmaceutical will receive an upfront payment and future milestone payments, including royalties on product sales.
  • Under the terms of the agreement, Chiesi will make an upfront payment and additional contingent milestone payments to Haisco, including royalties on product sales.

Chiesi Group signed a License Agreement with Haisco Pharmaceutical to develop, manufacture, and commercialise a novel, reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis

Retrieved on: 
Monday, November 20, 2023
Bronchiectasis, Respiratory disease, Patient, End-user license agreement, Partnership, DPP1, Pharmaceutical industry, Chiesi Farmaceutici

Chiesi Group and Haisco Pharmaceutical will collaborate closely to develop HSK31858, a novel reversible dipeptidyl peptidase 1 (DPP1) inhibitor for respiratory diseases.

Key Points: 
  • Chiesi Group and Haisco Pharmaceutical will collaborate closely to develop HSK31858, a novel reversible dipeptidyl peptidase 1 (DPP1) inhibitor for respiratory diseases.
  • This agreement expands Chiesi's comprehensive R&D program in bronchiectasis, a respiratory disease with high unmet medical needs, for which no approved treatment is available to date.
  • Haisco Pharmaceutical will receive an upfront payment and future milestone payments, including royalties on product sales.
  • Under the terms of the agreement, Chiesi will make an upfront payment and additional contingent milestone payments to Haisco, including royalties on product sales.